Prevention of Nausea in Migraines Study
Evanston Premier Healthcare Research
Do you have acute migraines?
If so, you may qualify for a multicenter, randomized, double-blind, comparator-controlled, placebo-controlled study to assess the efficacy and safety of oral CL-H1T in the treatment of acute migraine pain, with or without aura, and the prevention of migraine-associated nausea and vomiting (MANV).
You may qualify if:
- You are male or female ages 18 to 65.
- You have a history of episodic migraine for at least 1 year.
- You have 2 to 8 migraine attacks per month; at least 48 hours of headache-free time between migraine attacks.
- You have a history of migraine headache with nausea more than 50% of the time.